Lovastatin induces p21WAF1/CiP1 in human vascular smooth muscle cells: Influence on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition

International Journal of Molecular Medicine

Volumn 3, Issue 1, 1999, Pages 63-68

  Müller, Garsten ^b   Kiehl, Michael G ^a   Van De Loo, Jürgen ^a   Koch, Olaf M ^a,c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Paracelsus Clinic   (Germany)

Author keywords

Apoptosis; Cell cycle; Lovastatin; P21WAF1 Cip1; Protein phosphorylation; Smooth muscle cells

Indexed keywords

CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; TYROSINE;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIVISION; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; HUMAN; METABOLISM; PHOSPHORYLATION; VASCULAR SMOOTH MUSCLE;

APOPTOSIS; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; TYROSINE;

EID: 0032622497     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.3.1.63     Document Type: Article

References (26)

1. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389,1994.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al: Prevention of coronary heart disease with pravastatin in men with hypercholestcrolemia. West of Scotland Coronary Prevention Study Group. N Engl J Mcd 333: 1301-1307,1995.
3. Jukema JW, Bruschke AV, van Bovcn AJ, Reiber JH, Bal ET, Zwinderman AH, et al: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91: 2528-2540, 1995.
4. Faxon DP and Currier JW: Prevention of post-PTCA rcstcnosis. Ann NY Acad Sei 748:419-427, 1995.
5. Sahni R, Maniet AR, Voci G and Banka VS: Prevention of restcnosis by lovastatin after successful coronary angioplasly. Am Heart J 121: 1600-1608, 1991.
6. Vermylen J: Clinical trials of primary and secondary prevention of thrombosis and restenosis. Thromb Hacmost 74: 377-381,1995.
7. Corsini A, Raitcri M, Soma MR, Bernini F, Fumagalli R and Paolctti R: Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylelutaryl cocnzyme A reductasc inhibitors Am J Cardiol 76: 21A-28A, 1995.
8. Wcintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB III, Ivanhoe R, et al: Lack of effect of lovastatin on restcnosis after coronary angioplasty. Lovastatin Restcnosis Trial Study Group. N Engl J Med 331: 1331-1337,1994.
9. Treasure CB, Klein JL, Weintraub WS, Talley D, Stillabowcr ME, Kosinski AS, et al: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332: 481-487, 1995.
10. Soma MR, Donctfi E, Parolini C, Mazzini G, Ferrari C, Fumagalli R, et al: HMG CoA rcductase inhibitors. In vivo effects on carotid intimai thickening in normocholesterolemic rabbits. Arterioscler Thromb 13: 571-578, 1993.
11. Satoh T, Nakafuku M and Kaziro Y: Function of Ras as a molecular switch in signal transduction. J Biol Chem 267: 24149-24152, 1992.
12. Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature 343: 425-430,1990.
13. Glomset JA, Gelb MH and Farnsworth CC: Prenyl proteins in eukaryotic cells: a new type of membrane anchor. Trends BiochemSci 15: 139-142, 1990.
14. Jackson JH, Cochranc CG, Bourne JR, Solski PA, Buss JE and Der CJ: Farnesol modification of Kirstcn-ras exon 4B protein is essential for transformation. Proc Natl Acad Sei USA 87: 3042-3046, 1990.
15. Munro E, Patel M, Chan P, Betteridge L, Clunn G, Gallagher K, et al: Inhibition of human vascular smooth muscTe cell proliferation by lovastatin: the role of isoprcnoid intermediates of cholesterol synthesis. Eur J Clin Invest 24: 766-772, 1994.
16. Jones KD, Couldwell WT, Hinton DR, Su Y, He S, Anker L, et al: Lovastatin induces growth inhibition and apoptosis in human malicnant glioma cells. Biochem Biophys Res Commun 205: 1681-1687, 1994.
17. Jakobisiak M, Bruno S, Skierski JS and Darzynkiewicz Z: Cell cycle-specific effects of lovastatin. Proc Natl Acad Sei USA 88: 3628-3632, 1991.
18. Gospodarowicz D: Purification of a fibroblast growth factor from bovine pituitary. J Biol Chem 250: 2515-2520, 1975.
19. Far DF, Peyron JF, Imbcrt V and Rossi B: Immunofluorescent quantification of tyrosine phosphorylation of cellular proteins in whole cells by flow cytometry. Cytometry 15: 327-334, 1994.
20. Müller C, Sindermann J, Banger N and Koch O: Loss in protein phosphorylation and apoptosis are induced by inhibition of mevalonate pathway in bcr-abl positive K562 leukemic cell line. Exp Hematol 23: a826, 1995.
21. Perez-Sala D and Mollinedo F: Inhibition of isoprenoid biosynthesis induces apoptosis in human promyclocytic HL-60 cells. Biochem Biophys Res Commun 199: 1209-1215, 1995.
22. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, et al: p53-dependent inhibition of cyclin-dependent I kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023, 1994.
23. Indolfi C, Avvedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, et al: Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. I Nat Mcd 1:541-545, 1995.
24. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al: WAF, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
25. Foley DP, Bonnier H, Jackson G, Macaya C, Shepherd J, Vrolix M, et al: Prevention of restcnosis after coronary balloon angioplasty: rationale and design of the fluvastatin angioplasty restenosis (FLARE) trial. The FLARE Study Group. Am J Cardiol 73:500-610,1994.
26. Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, el ai: The physiological disposition of lovastatin. Drug Metab Dispos 17: 166-173, 1989.